Craniofacial development in children with cystic fibrosis
American Journal of Orthodontics and Dentofacial Orthopedics · 2026-06 · 169 (6) · 766-775
DOI: 10.1016/j.ajodo.2025.12.014 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Orthodontics and Dentofacial Orthopedics, 2026-06. Verfasst von Nazlı Gonder Erdede und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthodontics, Faculty of Dentistry, Harran University, Şanlıurfa, Turkey. Hauptthemen laut MEDLINE: Cystic Fibrosis, Maxillofacial Development. Die Arbeit nennt 36 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
INTRODUCTION: Cystic fibrosis (CF) is a genetic disorder affecting multiple systems and is often associated with nasal congestion, rhinorrhea, and mouth breathing because of upper respiratory tract involvement. These factors may influence craniofacial growth. This study aimed to evaluate craniofacial morphology in children with CF. METHODS: Fifty-six Turkish participants were included: 28 children with CF (14 boys and 14 girls; mean age = 12.10 ± 2.74 years) and 28 age- and sex-matched healthy controls (14 boys and 14 girls; mean age = 12.14 ± 2.74 years). Craniofacial features were assessed using cephalometric radiographs and maxillary digital models. Descriptive characteristics were compared using the chi-square test, and group differences were analyzed using the independent-samples t test. RESULTS: The sagittal skeletal classification revealed that patients with CF were 32.1% Class I, 35.7% Class II, and 32.1% Class III skeletal bases. Class I malocclusion was the most common (85.7%). In the control group, Class I skeletal relationships and malocclusion patterns were most prevalent (89.3%). Children with CF showed a statistically significant decrease in Ricketts maxillary width, and smaller SNA and SNB values (58.93 ± 3.55 mm, 79.51° ± 3.26°, and 76.43° ± 2.89°, respectively) than controls (64.03 ± 4.05 mm, 81.73° ± 2.60°, and 79.26° ± 2.47°, respectively). Conversely, the CF group had a higher Frankfort mandibular plane angle, a lower anterior facial height (LAFH), and LAFH% values (29.66° ± 2.90°, 66.0 ± 4.03 mm, and 57.09% ± 1.01%) than controls (25.91° ± 1.59°, 60.52 ± 2.67 mm, and 53.33% ± 1.16%). Digital model analysis showed a significantly reduced palatal width and palatal curvature angle (the mean difference was -2.36, -2.57, -3.06, and -3.77 mm for palatal width and -9.46°, -10.91°, -10.67°, and -11.67° for palatal curvature angle at the canine, first premolar, second premolar, and first molar teeth, respectively) and increased palatal depth (the mean difference was 0.41, 1.20, 1.64, 1.69 mm at the canine, first premolar, second premolar, and first molar regions, respectively), in the CF group (P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Orthodontics, Faculty of Dentistry, Harran University, Şanlıurfa, Turkey.
- Department of Orthodontics, Faculty of Dentistry, Gaziantep University, Gaziantep, Turkey. Electronic address: ayseguldt@yahoo.com.
- Department of Pediatric Gastroenterology, Gaziantep City Hospital, Gaziantep, Turkey.
- Department of Pediatric Chest Diseases, Gaziantep City Hospital, Gaziantep, Turkey.
Zitieren
APA
Erdede, N. G., Gulec, A., Sahin, Y., & Asfuroglu, P. (2026). Craniofacial development in children with cystic fibrosis. American Journal of Orthodontics and Dentofacial Orthopedics, 169(6), 766-775. https://doi.org/10.1016/j.ajodo.2025.12.014
Vancouver
Erdede NG, Gulec A, Sahin Y, Asfuroglu P. Craniofacial development in children with cystic fibrosis. American Journal of Orthodontics and Dentofacial Orthopedics. 2026;169(6):766-775. doi:10.1016/j.ajodo.2025.12.014
BibTeX
@article{Erdede2026,
author = {Erdede, Nazlı Gonder and Gulec, Aysegul and Sahin, Yasin and Asfuroglu, Pelin},
title = {Craniofacial development in children with cystic fibrosis},
journal = {American Journal of Orthodontics and Dentofacial Orthopedics},
year = {2026},
volume = {169},
number = {6},
pages = {766--775},
doi = {10.1016/j.ajodo.2025.12.014}
}
EUVIMED